Novocure Q2 net revenue $183.6M (+16% YoY); raises FY 2026 guidance

NovoCure Ltd

2026-Q2 EPS reported -$0.75 revenue$357,639,000

Net revenue $183.6M, up 16% YoY; net loss $15.7M ($0.13 loss per share).
Adjusted EBITDA $10.8M; gross margin 78% vs 74% a year ago.
FY 2026 revenue guidance raised to $710M-$725M (prev $690M-$710M); adjusted EBITDA guidance raised to $0M-$15M.
CE Mark received for Optune Pax for locally advanced pancreatic cancer; 285 active patients on Optune Pax in U.S.
Global active patients 5,128, up 11% YoY for Optune Gio; Optune Lua active patients up 51%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.